Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TMPRSS11E-CCR split-CAR T cells
- Development stage
- Preclinical
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TMPRSS11E-CCR split-CAR T cells are an experimental, preclinical-stage cellular immunotherapy designed for the treatment of multiple myeloma. This therapy utilizes an 'AND-gate' split-CAR architecture to enhance tumor specificity and mitigate on-target, off-tumor toxicities. The system consists of two separate constructs co-expressed in T cells: a first-generation CAR targeting TNFRSF8 (CD30) containing only the CD3ζ signaling domain, and a chimeric co-stimulatory receptor (CCR) targeting TMPRSS11E containing only the co-stimulatory domain. Potent T cell activation occurs only upon simultaneous binding of both TNFRSF8 and TMPRSS11E on the surface of a tumor cell. Both targets were identified through cell surface proteomics as being highly expressed in multiple myeloma with minimal overlapping expression in vital normal tissues.
- Other names
- TNFRSF8-CD3z / TMPRSS11E-CCR split-CAR T cells
02
Targets
CD30 (CD30 antigen)TMPRSS11E (Transmembrane serine protease 11E)
Beyond the preview
Go deeper on TMPRSS11E-CCR split-CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TMPRSS11E-CCR split-CAR T cells.